John Rex has become chief medical officer of F2G Ltd, a UK company that is developing treatments for invasive fungal infections. Dr Rex has been a non-executive director of F2G since 2012 whilst also working at AstraZeneca Plc where he was head of infection in the global medicine development division.
Prior to joining AstraZeneca, he was professor of medicine at the University of Texas Medical School at Houston. He holds a BA in biochemistry from Rice University and a medical degree from the Baylor College of Medicine in Texas.
F2G announced the appointment on 5 December 2016.
Copyright 2016 Evernow Publishing Ltd